CRANBURY, N.J., Sept. 12, 2017 /PRNewswire/ -- Palatin
Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company
developing targeted, receptor-specific peptide therapeutics for the
treatment of diseases with significant unmet medical need and
commercial potential, announced today that Anthony M. Manning, Ph.D. was appointed to
Palatin's Board of Directors on September
7, 2017. Dr. Manning currently serves as the Senior
Vice President of Research at Momenta Pharmaceuticals, Inc.
(NASDAQ: MNTA), Cambridge, MA.
"We are pleased to welcome Anthony to our Board," said
John Prendergast, Ph.D., Chairman of
the Board of Palatin Technologies. "Anthony is an accomplished
pharmaceutical executive with extensive experience translating
research into innovative products. Earlier this year we
licensed bremelanotide, our Phase 3 treatment for female sexual
dysfunction, to AMAG Pharmaceuticals. As we now begin to
focus on the development of our earlier stage assets, Anthony will
provide valuable insights and perspective with respect to our
research, development and business strategy."
Dr. Manning, age 55, is responsible for research and the
discovery of novel products as the Senior Vice President of
Research at Momenta Pharmaceuticals, Inc. Since joining Momenta,
his team has advanced three novel autoimmune drugs into
development. Prior to Momenta, Dr. Manning was Vice President and
Head of Immunology Research for Biogen Idec, Inc. Before that, he
was Vice President and Global Head of Inflammation, Autoimmunity
and Transplantation Research at Roche Pharmaceuticals.
Anthony M. Manning holds a Ph.D.
from the University of Otago, New
Zealand, and has authored more than 100 peer-reviewed
publications and patents in the fields of signal transduction,
autoimmune diseases and drug discovery.
Davis Board Consultants of Boston,
MA assisted in the search.
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company
developing targeted, receptor-specific peptide therapeutics for the
treatment of diseases with significant unmet medical need and
commercial potential. Palatin's strategy is to develop products and
then form marketing collaborations with industry leaders in order
to maximize their commercial potential. For additional information,
please visit http://www.palatin.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/palatin-technologies-announces-appointment-of-anthony-m-manning-phd-to-board-of-directors-300517577.html
SOURCE Palatin Technologies, Inc.